REGN - リジェネロン・ファ―マシュ―ティカルズ (Regeneron Pharmaceuticals Inc.) リジェネロン・ファ―マシュ―ティカルズ

 REGNのチャート


 REGNの企業情報

symbol REGN
会社名 Regeneron Pharmaceuticals Inc. (リジェネロン・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 リジェネロン・ファーマシューティカルズ(Regeneron Pharmaceuticals Inc)は重症疾患に使われる医薬品の発見・発明・開発・生産・商品化を行うバイオ医薬品会社である。同社は眼疾患、高密度リポタンパク質(LDL)コレステロール、炎症性疾患の医薬品を商品化し、慢性関節リウマチ、喘息、アトピー性皮膚炎、疼痛、がん、感染症などの分野に開発する製品候補を有する。同社は、EYLEA(aflibercept)注射剤、Praluent(アリロクマブ)注射剤、ARCALYST(rilonacept)皮下注射剤、Kevzara(sarilumab)皮下注射剤、ZALTRAP(ziv-aflibercept)注射剤を販売する。   リジェネロン・ファ―マシュ―ティカルズは米国の大手バイオ医薬品会社。主にがん、眼病、炎症に対する治療薬の開発、製造、販売に従事。主要な製品は加齢黄斑変性症と網膜中心静脈閉塞の黄斑浮腫治療薬「EYLEA」、転移性結腸直腸がん治療薬「ZALTRAP」、抗炎症剤「ARCALYST」など。本社はニューヨーク州。   Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
本社所在地 777 Old Saw Mill River Road Tarrytown NY 10591-6707 USA
代表者氏名 P. Roy Vagelos P. Roy Vagelos
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 914-347-7000
設立年月日 32143
市場名 NASDAQ National Market System
ipoyear 1991年
従業員数 6200人
url www.regeneron.com
nasdaq_url https://www.nasdaq.com/symbol/regn
adr_tso
EBITDA EBITDA(百万ドル) 2430.382
終値(lastsale) 394.17
時価総額(marketcap) 42592570691.16
時価総額 時価総額(百万ドル) 41378.5
売上高 売上高(百万ドル) 6202.627
企業価値(EV) 企業価値(EV)(百万ドル) 40400.885
当期純利益 当期純利益(百万ドル) 1917.428
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Regeneron Pharmaceuticals Inc revenues increased 12% to $3.12B. Net income increased 62% to $1.03B. Revenues reflect Net product sales increase of 11% to $1.98B Bayer Collaboration Revenue increase of 26% to $510.8M Other revenue increase of 16% to $197.2M. Net income benefited from Payroll and Benefits decrease of 4% to $280.7M (expense).

 REGNのテクニカル分析


 REGNのニュース

   Is Regeneron Pharmaceuticals (REGN) a Worthy Stock to Pick?  2020/01/21 08:30:00 Zacks Investment Research
Is Regeneron Pharmaceuticals (REGN) a great pick from the value investor's perspective right now? Read on to know more.
   Growth Differentiation Factor 8, Pipeline Review, H2 2019 - Biogen Inc, PeptiDream Inc, Pfizer & Regeneron Pharmaceuticals Inc - ResearchAndMarkets.com  2020/01/17 13:27:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Growth Differentiation Factor 8 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Summary According to the recently published report 'Growth Differentiation Factor 8 - Pipeline Review, H2 2019'; Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 10 molecules. Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8
   What to Expect from Amgen and Regeneron Stock in 2020, According to an Analyst  2019/12/24 14:03:00 Barron's
In notes on Monday afternoon, Raymond James analyst Dane Leone initiated coverage of Regeneron Pharmaceuticals and Amgen at Market Perform, writing that the current valuation of each of the stocks is fair.
   Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations  2019/12/10 17:28:09 Benzinga
Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) shares were rebounding Tuesday as investors digested French pharma giant and collaboration partner Sanofi SA's (NASDAQ: SNY ) potential liquidation of its Regeneron stake — and the restructuring of a collaboration agreement between the two. Hints At Regeneron Stake Sale At Sanofi's Capital Markets Day, the company announced a slew of measures intended to drive innovation and growth. Apart from prioritizing key growth drivers — Dupixent and vaccines — and accelerating an R&D focus on six potentially transformative medicines, Sanofi said it would improve operating efficiencies to fund growth. While discussing its capital allocation policy, Sanofi said that, apart from cash generated from its businesses, it has the wherewithal to raise capital through asset disposals and monetizing its stake in Regeneron after the lockup period expires in December 2020. See Also: 5 Stocks Moving On ASH Presentations The Sanofi-Regeneron Collaboration Sanofi and Regeneron entered a global collaboration agreement in November 2007 to develop fully human therapeutics antibodies using the latter's VelociSuite technologies.
   Did Hedge Funds Drop The Ball On Regeneron Pharmaceuticals Inc (REGN) ?  2019/12/05 01:33:58 Yahoo Finance
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an
   Assessing If Regeneron Is In Value Territory After Shares Tumble  2019-05-08
Ahead of first-quarter results, Regeneron ( REGN ) shares fell from the $400-440 level and below its major 50- and 200-day moving averages. When the company failed to meet Wall Street expectations, shares fell another 6%. Sales of its atopic dermatitis drug Dupixent are growing and stand to be…
   Equities Try To Steady After Selloff (Wall Street Breakfast Podcast)  2019-05-08
Today's Top Stories: Equities try to steady after selloff; Iran begins withdrawal from nuclear deal; and pound on edge as support builds to oust May. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find…
   Wall Street Breakfast: Equities Try To Steady After Selloff  2019-05-08
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Wall Street is looking to stabilize following last night's 473 point fall for the DJIA, as Chinese t…
   Assessing If Regeneron Is In Value Territory After Shares Tumble  2019-05-08
Ahead of first-quarter results, Regeneron ( REGN ) shares fell from the $400-440 level and below its major 50- and 200-day moving averages. When the company failed to meet Wall Street expectations, shares fell another 6%. Sales of its atopic dermatitis drug Dupixent are growing and stand to be…
   Equities Try To Steady After Selloff (Wall Street Breakfast Podcast)  2019-05-08
Today's Top Stories: Equities try to steady after selloff; Iran begins withdrawal from nuclear deal; and pound on edge as support builds to oust May. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find…
   Wall Street Breakfast: Equities Try To Steady After Selloff  2019-05-08
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Wall Street is looking to stabilize following last night's 473 point fall for the DJIA, as Chinese t…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リジェネロン・ファ―マシュ―ティカルズ REGN Regeneron Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)